Springworks Therapeutics (SWTX) said Monday that the European Commission has granted marketing authorization for Ogsiveo, or nirogacestat, for the treatment of adults with progressing desmoid tumors.

The company said the approval was based on the results of a late-stage trial, where Ogsiveo met the primary endpoint of improving progression-free survival.

Ogsiveo is also approved in the US for the treatment of adult patients with progressing desmoid tumors who require systemic treatment, the company said.